Business
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting
PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from Septembe
About this update from Treace Medical Concepts, Inc.
[{"type":"image","alt":"Treace Medical Concepts, Inc.","displaySize":"","headline":null,"caption":"Treace Medical Concepts, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vLorRmISLl3PfaqwwnfXfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363","width":300,"height":60}},"lazy":false},{"type":"text","content":"PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from September 10-13, 2025.","length":518,"tagName":"p"},{"type":"text","content":"“We are excited to highlight the full commercial release of our expanded bunion portfolio at AOFAS, which now provides surgeons with best-in-class solutions to address the entire spectrum of bunion surgery,” said John T. Treace, CEO, Founder and Chairman of Treace. “With the addition of Nanoplasty®, Percuplasty™, SpeedMTP®, and IntelliGuide™ PSI, we are building on the success of Lapiplasty® and Adductoplasty® to advance our Company’s focused mission to improve surgical outcomes for bunion patients. We also look forward to sharing compelling clinical evidence from prospective, multicenter studies that continues to differentiate our flagship Lapiplasty® and Adductoplasty® procedures.”","length":702,"tagName":"p"},{"type":"text","content":"Treace will feature clinical data, several new technologies at its AOFAS exhibit booth and host surgeon training events on these innovations, including:","length":152,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nanoplasty® MIS 3D Bunion Correction: The Nanoplasty® procedure is designed to accelerate surgeon access to 3D MIS osteotomies and is performed through a single 1.5cm hidden incision on the side of the foot. Nanoplasty® is a disruptive system for rap...